Microbot Medical Secures Key China Patent for LIBERTY Robotic Surgery System | MBOT Stock News

By Editorial Team

Microbot Medical, a leading medical technology company listed on NASDAQ under the ticker symbol MBOT, has recently announced the acquisition of a crucial patent in China for its LIBERTY Endovascular Robotic System. The patent, granted by the China National Intellectual Property Administration (CNIPA), specifically covers the robotic manipulation of surgical tool handles, enhancing Microbot's global intellectual property (IP) portfolio.

Key Highlights:

• Microbot Medical strengthens its global IP portfolio with the newly granted patent in China for the LIBERTY System.
• The company now boasts a total of 9 granted patents and 59 pending applications worldwide.
• Anticipated commercial launch of the LIBERTY System in the U.S. is set for Q3 2025, pending FDA clearance.
• The U.S. market sees approximately 2 million peripheral endovascular procedures annually, with 2.9 million in China.
• The patent reinforces Microbot's IP protection and supports its global commercialization strategy, particularly in key markets like China.

The LIBERTY Endovascular Robotic System is a groundbreaking innovation designed to revolutionize endovascular robotics and enhance patient care globally. With this recent patent grant in China, Microbot Medical has fortified its position in the competitive medical technology landscape, preparing for the imminent commercial launch of the LIBERTY System in the United States.

Microbot's strategic focus on expanding its IP portfolio underscores the company's commitment to driving innovation and maintaining a competitive edge in the rapidly evolving field of surgical robotics. The patent's coverage of robotic tool manipulation further solidifies Microbot's technological advancements and sets the stage for a successful market entry.

As Microbot progresses towards the anticipated commercial launch of the LIBERTY System in the U.S., the newly acquired patent in China serves as a significant milestone in the company's journey towards establishing a strong global presence in the endovascular robotics market.

For more information about Microbot Medical and the LIBERTY Endovascular Robotic System, visit Microbot Medical's official website.